本帖最后由 老马 于 2012-1-13 21:20 编辑
1 ]3 h) w/ l# d0 U5 L6 Y9 V2 E: E. k4 v) s+ M5 o
爱必妥和阿瓦斯丁的比较. \0 t/ x1 @' b8 a1 A
6 ~& }$ J* C+ Z; _1 j& ^
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/* Q. I: S( c8 L! u1 g
9 ~0 Q5 g n7 S: c4 W# c
. u+ z4 [2 Y' k+ q- L. A" ~http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/: Q- }) Z, a% O! _ s8 S* |
==================================================
' B+ Z% H/ L5 R, D& ^Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 S" u/ q4 z0 n, P1 c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.! M+ k1 q% j! K3 X* I7 y
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 e9 L9 }1 P7 \) Q W. T7 a* v; h
|
显身卡
